P072 Low Detection Rate of EGFR Driver and T790M Mutation in Plasma by Cobas V2 After Acquired Resistance to Afatinib

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.085
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Detection of Epidermal Growth Factor Receptor Gene T790M Mutation in Cytology Samples Using the Cobas ® EGFR Mutation Test

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2017English

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2019English

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2018English

Rebiopsy of Lung Cancer Patients With Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Clinical Cancer Research
Cancer ResearchOncology
2011English

Newly Emergent Acquired EGFR Exon 18 G724S Mutation After Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-Cell Lung Cancer: A Case Report

OncoTargets and Therapy
OncologyPharmacology
2018English

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy